RANI

Rani Therapeutics Holdings, Inc. is a clinical-stage biotherapeutics company focused on advancing technologies to enable the development of orally administered biologics and drugs. The Company has developed the RaniPill capsule, which is a proprietary and patented platform technology, intended to replace subcutaneous injection or intravenous infusion of biologics and drugs with oral dosing. The RaniPill capsule is designed to deliver a variety of drug substances, including antibodies, proteins, peptides, and oligonucleotides. It has two configurations of the platform: the RaniPill GO and the RaniPill HC. The RaniPill GO is designed to deliver up to a 3 mg dose of drug in microtablet form with high bioavailability. It is also developing a high-capacity version of the RaniPill capsule known as the RaniPill HC. Its product candidate pipeline includes obesity programs (RT-114 and RT-116), immunology programs (RT-105 and RT-111) and endocrinology programs (RT-102 and RT-110).

Wall Street analysts forecast RANI stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for RANI is 10.00 USD with a low forecast of 9.00 USD and a high forecast of 11.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.

Rani Therapeutics Holdings Inc revenue for the last quarter amounts to 0.00 USD, decreased % YoY.

Rani Therapeutics Holdings Inc. EPS for the last quarter amounts to -0.12 USD, decreased -50.00 % YoY.

Rani Therapeutics Holdings Inc (RANI) has 105 emplpoyees as of December 18 2025.

Today RANI has the market capitalization of 172.55M USD.